898 results on '"Jarolim, Petr"'
Search Results
102. ACTH treatment promotes murine cardiac allograft acceptance
103. Evaluation of Three Commercial and Two Non-Commercial Immunoassays for the Detection of Prior Infection to SARS-CoV-2
104. Correction to: Evaluation of serological lateral flow assays for severe acute respiratory syndrome coronavirus-2
105. Evaluation of serological lateral flow assays for severe acute respiratory syndrome coronavirus-2
106. Cardiovascular Biomarkers and Heart Failure Risk in Stable Patients With Atherothrombotic Disease: A Nested Biomarker Study From TRA 2°P‐TIMI 50
107. Additional file 1 of Evaluation of serological lateral flow assays for severe acute respiratory syndrome coronavirus-2
108. Diagnostic evaluation of the MRP-8/14 for the emergency assessment of chest pain
109. Exercise dynamics of cardiac biomarkers and hemoconcentration in patients with chronic systolic heart failure
110. Elevated serum soluble endoglin (sCD105) decreased during extracorporeal elimination therapy for familial hypercholesterolemia
111. Implementation of a highly sensitive cardiac troponin I assay: Test volumes, positivity rates and interpretation of results
112. Myocardial fibrosis in an early manifestation of hypertrophic cardiomyopathy
113. Statin-induced Kruppel-like factor 2 expression in human and mouse T cells reduces inflammatory and pathogenic responses
114. miR-15a/16-1 deletion in activated B cells promotes plasma cell and mature B-cell neoplasms
115. A Potassium-Based Quality-of-Service Metric Reduces Phlebotomy Errors, Resulting in Improved Patient Safety and Decreased Cost.
116. Serial assessment of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial
117. Serial Measurement of Monocyte Chemoattractant Protein-1 After Acute Coronary Syndromes: Results From the A to Z Trial
118. The effect of three major co‐morbidities on quality of life and outcome of patients with heart failure with reduced ejection fraction
119. Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease
120. Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium–glucose co‐transporter 2 inhibitor therapy in DECLARE‐TIMI 58
121. Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol Guidelines
122. Timing and magnitude if increases in levythyroxine requirements during pregnancy in women with hyperthyroidism
123. Refrigeration is not necessary for measurement of uric acid in patients treated with rasburicase
124. Intensive Statin Therapy and the Risk of Hospitalization for Heart Failure After an Acute Coronary Syndrome in the PROVE IT–TIMI 22 Study
125. Uncoupling between intravascular and distending pressures leads to underestimation of circulatory congestion in obesity.
126. Uncoupling between intravascular and distending pressures leads to underestimation of circulatory congestion in obesity.
127. Serum biomarkers for heart failure
128. Availability of energetic substrates and exercise performance in heart failure with or without diabetes
129. Method comparison of a 25-hydroxy vitamin D enzyme immunoassay to liquid chromatography tandem mass spectroscopy
130. The importance of correct assignment of CYP2B6 genetic variants with respect to cyclophosphamide metabolizer status
131. Assessment of multiple cardiac biomarkers in non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 Trial
132. Biomarkers of platelet activation and cardiovascular risk in the DAPT trial
133. Evaluation of two commercial and two non-commercial immunoassays for the detection of prior infection to SARS-CoV-2
134. Hypertrophic cardiomyopathy in myosin-binding protein C (MYBPC3) Icelandic founder mutation carriers
135. Cardiovascular Mortality After Type 1 and Type 2 Myocardial Infarction in Young Adults
136. Allelic variations in CYP2B6 and CYP2C19 and survival of patients receiving cyclophosphamide prior to myeloablative hematopoietic stem cell transplantation
137. Myocardial Fibrosis as an Early Manifestation of Hypertrophic Cardiomyopathy
138. Distinct Subgroups in Hypertrophic Cardiomyopathy in the NHLBI HCM Registry
139. Analysis and interpretation of drug testing results from patients on chronic pain therapy: a clinical laboratory perspective
140. Detection of acute changes in circulating troponin in the setting of transient stress test-induced myocardial ischaemia using an ultrasensitive assay: results from TIMI 35
141. The “cutting” edge: von Willebrand factor-cleaving protease activity in thrombotic microangiopathies
142. A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes.
143. Preoperative B-type natriuretic peptide is as independent predictor of ventricular dysfunction and mortality after primary coronary artery bypass grafting
144. Cancer Risk of Heterozygotes With the NBN Founder Mutation
145. Diagnostic and Prognostic Utility of Brain Natriuretic Peptide in Subjects Admitted to the ICU With Hypoxic Respiratory Failure Due to Noncardiogenic and Cardiogenic Pulmonary Edema*
146. Timing and Magnitude of Increases in Levothyroxine Requirements during Pregnancy in Women with Hypothyroidism
147. Substitution Glu480Lys in erythroid band 3 corresponds to the Fra blood group antigen and supports existence of the second ectoplasmic loop of band 3
148. Characterization of a highly polymorphic marker adjacent to the SLC4A1 gene and of kidney immunostaining in a family with distal renal tubular acidosis
149. Simultaneous (AC)n microsatellite polymorphism analysis and single-stranded conformation polymorphism screening is an efficient strategy for detecting ankyrin-1 mutations in dominant hereditary spherocytosis
150. Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: An analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.